389 related articles for article (PubMed ID: 21346614)
1. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Bruno A; Micò U; Pandolfo G; Mallamace D; Abenavoli E; Di Nardo F; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Ak M; Bulut SD; Bozkurt A; Ozsahin A
Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
7. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
11. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
Sayyah M; Sayyah M; Boostani H; Ghaffari SM; Hoseini A
Depress Anxiety; 2012 Oct; 29(10):850-4. PubMed ID: 22933237
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.
Storch EA; Lehmkuhl H; Geffken GR; Touchton A; Murphy TK
Depress Anxiety; 2008; 25(2):172-4. PubMed ID: 17340610
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
[TBL] [Abstract][Full Text] [Related]
16. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
Bruno A; Pandolfo G; Cedro C; Gallo G; De Felice M; Zoccali RA; Muscatello MR
Clin Neuropharmacol; 2016; 39(1):6-9. PubMed ID: 26757309
[TBL] [Abstract][Full Text] [Related]
17. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Sarkar R; Klein J; Krüger S
Psychopharmacology (Berl); 2008 May; 197(4):687-8. PubMed ID: 18264798
[No Abstract] [Full Text] [Related]
19. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
[TBL] [Abstract][Full Text] [Related]
20. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
